HSP90AB1 and breast carcinoma: However, targeting the C-terminal domain (CTD) has been poorly studied in breast cancer models, while developing novel HSP90 inhibitors that target the CTD is recommended, since it does not induce the heat-shock response associated with N-terminal inhibitors and it was proven that inhibitors that do not induce heat-shock response could potentially have better clinical applications [32,36,37,60].